A Thiel Fellow's Defense Biotech Startup Raises $25 Million for Biosurveillance

The startup, founded by Thiel Fellow Jake Adler, is developing a portable genomic sequencer to spot chemical and biological threats, reportedly with an initial CDC deployment.

About PILGRIMS

Published

The most expensive mistake a robot can make is the one it doesn't know it made. For a machine deployed in a warzone or a high-risk lab, that mistake could be a missed pathogen or an undetected nerve agent. The cost is measured in lives, not just downtime. This is the problem space Pilgrim, a defense biotechnology startup, has decided is worth a $150 million valuation and a $25 million seed check [WOWTale, September 2026].

Its answer is a three-pronged product suite with a clear, grim logic: stop the bleeding, neutralize the threat, and see it coming next time. While the hemostatic dressing and inhaled countermeasure are dramatic, the unit economics of prevention are where the real climate of risk gets reshaped. Pilgrim's biosurveillance platform, ARGUS, is a bet that spotting a biological or chemical threat minutes earlier is worth billions in averted crisis.

A product suite for catastrophic moments

Pilgrim is not building a general-purpose robotics framework, despite some early branding. Its focus, according to investor reports and coverage, is squarely on defense biotech [Business Insider, August 2025]. The product lineup reads like a checklist for a field medic facing a sci-fi scenario.

  • Kingsfoil. A clay-based hemostatic dressing designed to seal severe bleeding rapidly. Founder Jake Adler famously demonstrated the product on himself in a funding pitch video [Business Insider, August 2025].
  • Voyager. An inhaled countermeasure intended to neutralize chemical threats like nerve agents.
  • ARGUS. The strategic centerpiece. Reported as a roughly 50-pound unit that combines air sampling and genomic sequencing to detect chemical and biological threats in the environment [WOWTale, September 2026].

The through-line is autonomy in high-stakes, time-sensitive situations where human expertise may be absent or overwhelmed. ARGUS, in particular, aims to automate the detection loop,constantly monitoring, diagnosing, and logging threats so the system, theoretically, learns and improves.

Why Buckley Ventures wrote the check

A $25 million seed round is a substantial declaration of faith, especially for hardware-adjacent deep tech. The round, reportedly led by Buckley Ventures at a $150 million valuation, attracted a notable list of backers including Peter Thiel, Coinbase co-founder Fred Ehrsam, and Brian Armstrong [AI Weekly, retrieved 2026] [Traded: Venture Capital on X, retrieved 2026]. The investor signal is less about a single product and more about the strategic category of automated biodefense.

The bet appears to be on the convergence of a few trends: the decreasing cost and size of genomic sequencing, rising geopolitical tensions that make biosurveillance a national priority, and a defense procurement apparatus that may be more open to agile, venture-backed suppliers. For investors, Pilgrim represents a wedge into the lucrative and traditionally slow-moving biodefense market.

Round Date Amount Lead Investor Key Backers
March 2025 $3.25M Not Disclosed Thiel Capital, Cantos, Refactor Capital [Perplexity Sonar Pro Brief, 2026]
August 2025 $4.3M Cantos Thiel Capital, Day One Ventures, angels [Business Insider, August 2025]
September 2026 $25M Buckley Ventures Peter Thiel, Fred Ehrsam, Brian Armstrong, Dylan Field [WOWTale, September 2026]

The founder's unusual wedge

The company's trajectory is inextricably linked to its founder, Jake Adler. He started Pilgrim after leaving high school in 2022 and was named a Thiel Fellow in 2023 [Business Insider, August 2025] [jakeradler.com, retrieved 2026]. The Thiel Fellowship, which grants $100,000 to young entrepreneurs to skip college and build, provides more than capital; it offers a network and a stamp of approval for unconventional, high-conviction bets.

Adler's co-founders bring a different kind of experience. Anurag Kedia, listed as CEO in some sources, is an IIT Bombay and IIM Ahmedabad alumnus with a background in building a direct-to-consumer brand [Fireside Ventures, retrieved 2026] [Inc42.com, retrieved 2026]. Gagan Deep Makker is also an IIT Bombay alumnus and co-founder [LinkedIn, retrieved 2026]. This suggests a team combining technical ambition with operational grounding, though the division of roles between the defense biotech and the unrelated D2C beauty brand of the same name is unclear in the public record.

The deployment question

The most critical claim supporting Pilgrim's valuation is customer traction. A September 2026 report stated that the ARGUS system "had already been deployed across the United States under a biosurveillance agreement with the U.S. Centers for Disease Control and Prevention" [WOWTale, September 2026]. This claim has not been independently verified by other sources or formally announced by the company, which the same report notes.

If true, it would be a monumental feat for a seed-stage startup, essentially bypassing years of typical government procurement cycles. If overstated, it represents the single largest risk to the company's narrative. The path from a prototype to a deployed, trusted national infrastructure asset is fraught with technical validation, regulatory hurdles, and fierce competition from established defense contractors.

The unit economics of prevention

The financial logic of Pilgrim, particularly for ARGUS, rests on a simple calculation. The cost of a widespread biological incident,in healthcare expenses, economic shutdown, and loss of life,can run into the hundreds of billions. The Defense Department's budget for chemical and biological defense programs is measured in billions annually. If a network of autonomous detectors can provide even a few hours of earlier warning, the value of that intelligence is immense, even if each unit costs tens of thousands of dollars.

A back-of-the-envelope sketch: if ARGUS units were deployed at 500 high-traffic transit sites or government buildings at a cost of $50,000 per unit (including maintenance), the initial hardware capex would be $25 million. That's roughly the size of Pilgrim's latest seed round. The ongoing service and data subscription revenue could then build the business. The incumbent it must beat isn't another startup; it's the inertia of existing, manual sampling methods and the slow-moving giants like Leidos or Battelle that currently fulfill government contracts. Pilgrim's bet is that a smaller, smarter, and faster-moving unit can own the new category of automated, networked biosurveillance.

Sources

  1. [Business Insider, August 2025] Pilgrim’s Jake Adler Secures $4.3 Million by Demoing … | https://www.businessinsider.com/pilgrim-jake-adler-4-million-funding-biotech-product-bold-video-2025-8
  2. [WOWTale, September 2026] Defense Biotech Pilgrim Raises $25M Seed at $150M Valuation | https://en.wowtale.net/2026/09/28/235250/
  3. [Perplexity Sonar Pro Brief, retrieved 2026] Pilgrim funding summary | Not available
  4. [AI Weekly, retrieved 2026] Pilgrim funding report | Not available
  5. [Traded: Venture Capital on X, retrieved 2026] Pilgrim funding announcement | Not available
  6. [jakeradler.com, retrieved 2026] Jake Adler personal site | https://jakeradler.com/
  7. [Fireside Ventures, retrieved 2026] Anurag Kedia | Pilgrim | Fireside Ventures | https://firesideventures.com/blogs/founders/anurag-kedia
  8. [Inc42.com, retrieved 2026] Anurag Kedia profile | Not available
  9. [LinkedIn, retrieved 2026] Gagandeep M. - Pilgrim | LinkedIn | https://www.linkedin.com/in/gaganmakker/

Read on Startuply.vc